VERTEX PHARMACEUTICALS INC / MA Share-based Payment Arrangement, Expense, after Tax
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Share-based Payment Arrangement, Expense, after Tax of $134.90 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax · last filed 2026-08-04
- VERTEX PHARMACEUTICALS INC / MA share-based payment arrangement, expense, after tax for the quarter ending 2026-06-30 was $134.90M, a 3.13% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA share-based payment arrangement, expense, after tax for the quarter ending 2026-03-31 was $131.10M, a 44.22% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA share-based payment arrangement, expense, after tax for the quarter ending 2025-12-31 was $188.20M, a 33.95% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA share-based payment arrangement, expense, after tax for the quarter ending 2025-09-30 was $147.40M, a 22.83% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA share-based payment arrangement, expense, after tax for fiscal 2025 was $557.30M, a 24.70% increase from fiscal 2024.
- VERTEX PHARMACEUTICALS INC / MA share-based payment arrangement, expense, after tax for fiscal 2024 was $446.90M, a 8.03% increase from fiscal 2023.
- VERTEX PHARMACEUTICALS INC / MA share-based payment arrangement, expense, after tax for fiscal 2023 was $413.70M, a 19.15% increase from fiscal 2022.
- VERTEX PHARMACEUTICALS INC / MA share-based payment arrangement, expense, after tax for fiscal 2022 was $347.20M, a 3.15% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense, after Tax 3 month | Share-based Payment Arrangement, Expense, after Tax 3 month as first filed | Share-based Payment Arrangement, Expense, after Tax 6 month | Share-based Payment Arrangement, Expense, after Tax 6 month as first filed | Share-based Payment Arrangement, Expense, after Tax 9 month | Share-based Payment Arrangement, Expense, after Tax 9 month as first filed | Share-based Payment Arrangement, Expense, after Tax 12 month | Share-based Payment Arrangement, Expense, after Tax 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $134.90M 10-Q · filed 2026-08-04 | $266.00M 10-Q · filed 2026-08-04 | $454.20M derived: sum of 3 quarters · filed 2026-08-04 | $601.60M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2026-03-31 | $131.10M 10-Q · filed 2026-05-05 | $319.30M derived: sum of 2 quarters · filed 2026-05-05 | $466.70M derived: sum of 3 quarters · filed 2026-05-05 | $597.50M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-12-31 | $188.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $335.60M derived: sum of 2 quarters · filed 2026-02-13 | $466.40M derived: sum of 3 quarters · filed 2026-08-04 | $557.30M 10-K · filed 2026-02-13 | ||||
| 2025-09-30 | $147.40M 10-Q · filed 2025-11-04 | $278.20M derived: sum of 2 quarters · filed 2026-08-04 | $369.10M 10-Q · filed 2025-11-04 | $509.60M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-06-30 | $130.80M 10-Q · filed 2026-08-04 | $221.70M 10-Q · filed 2026-08-04 | $362.20M derived: sum of 3 quarters · filed 2026-08-04 | $482.20M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-03-31 | $90.90M 10-Q · filed 2026-05-05 | $231.40M derived: sum of 2 quarters · filed 2026-05-05 | $351.40M derived: sum of 3 quarters · filed 2026-05-05 | $424.90M derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | $140.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $260.50M derived: sum of 2 quarters · filed 2026-02-13 | $334.00M derived: sum of 3 quarters · filed 2026-02-13 | $446.90M 10-K · filed 2026-02-13 | ||||
| 2024-09-30 | $120.00M 10-Q · filed 2025-11-04 | $193.50M derived: sum of 2 quarters · filed 2025-11-04 | $306.40M 10-Q · filed 2025-11-04 | $456.50M derived: sum of 4 quarters · filed 2026-02-13 | ||||
| 2024-06-30 | $73.50M 10-Q · filed 2025-08-05 | $186.40M 10-Q · filed 2025-08-05 | $336.50M derived: sum of 3 quarters · filed 2026-02-13 | $430.30M derived: sum of 4 quarters · filed 2026-02-13 | ||||
| 2024-03-31 | $112.90M 10-Q · filed 2025-05-06 | $263.00M derived: sum of 2 quarters · filed 2026-02-13 | $356.80M derived: sum of 3 quarters · filed 2026-02-13 | $444.80M derived: sum of 4 quarters · filed 2026-02-13 | ||||
| 2023-12-31 | $150.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $243.90M derived: sum of 2 quarters · filed 2026-02-13 | $331.90M derived: sum of 3 quarters · filed 2026-02-13 | $413.70M 10-K · filed 2026-02-13 | ||||
| 2023-09-30 | $93.80M 10-Q · filed 2024-11-05 | $181.80M derived: sum of 2 quarters · filed 2024-11-05 | $263.60M 10-Q · filed 2024-11-05 | $332.30M derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2023-06-30 | $88.00M 10-Q · filed 2024-08-02 | $169.80M 10-Q · filed 2024-08-02 | $238.50M derived: sum of 3 quarters · filed 2025-02-13 | $335.30M derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2023-03-31 | $81.80M 10-Q · filed 2024-05-07 | $150.50M derived: sum of 2 quarters · filed 2025-02-13 | $247.30M derived: sum of 3 quarters · filed 2025-02-13 | $334.70M derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2022-12-31 | $68.70M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $165.50M derived: sum of 2 quarters · filed 2025-02-13 | $252.90M derived: sum of 3 quarters · filed 2025-02-13 | $347.20M 10-K · filed 2025-02-13 | ||||
| 2022-09-30 | $96.80M 10-Q · filed 2023-11-07 | $184.20M derived: sum of 2 quarters · filed 2023-11-07 | $278.50M 10-Q · filed 2023-11-07 | $387.90M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2022-06-30 | $87.40M 10-Q · filed 2023-08-02 | $181.70M 10-Q · filed 2023-08-02 | $291.10M derived: sum of 3 quarters · filed 2024-02-15 | $372.50M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2022-03-31 | $94.30M 10-Q · filed 2023-05-02 | $203.70M derived: sum of 2 quarters · filed 2024-02-15 | $285.10M derived: sum of 3 quarters · filed 2024-02-15 | $368.80M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2021-12-31 | $109.40M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $190.80M derived: sum of 2 quarters · filed 2024-02-15 | $274.50M derived: sum of 3 quarters · filed 2024-02-15 | $358.50M 10-K · filed 2024-02-15 | ||||
| 2021-09-30 | $81.40M 10-Q · filed 2022-10-28 | $81.44M 10-Q · filed 2021-11-03 | $165.10M derived: sum of 2 quarters · filed 2022-10-28 | $249.10M 10-Q · filed 2022-10-28 | $249.13M 10-Q · filed 2021-11-03 | $329.76M derived: sum of 4 quarters · filed 2023-02-10 | ||
| 2021-06-30 | $83.70M 10-Q · filed 2022-08-05 | $83.77M 10-Q · filed 2021-07-30 | $167.70M 10-Q · filed 2022-08-05 | $167.69M 10-Q · filed 2021-07-30 | $248.36M derived: sum of 3 quarters · filed 2023-02-10 | $312.60M derived: sum of 4 quarters · filed 2023-02-10 | ||
| 2021-03-31 | $83.90M 10-Q · filed 2022-05-06 | $83.92M 10-Q · filed 2021-04-30 | $164.66M derived: sum of 2 quarters · filed 2023-02-10 | $228.90M derived: sum of 3 quarters · filed 2023-02-10 | $314.94M derived: sum of 4 quarters · filed 2023-02-10 | |||
| 2020-12-31 | $80.76M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-10 | $145.00M derived: sum of 2 quarters · filed 2023-02-10 | $231.04M derived: sum of 3 quarters · filed 2023-02-10 | $282.50M 10-K · filed 2023-02-10 | $282.50M 10-K · filed 2021-02-11 | |||
| 2020-09-30 | $64.24M 10-Q · filed 2021-11-03 | $150.28M derived: sum of 2 quarters · filed 2021-11-03 | $201.74M 10-Q · filed 2021-11-03 | $256.78M derived: sum of 4 quarters · filed 2022-02-09 | ||||
| 2020-06-30 | $86.04M 10-Q · filed 2021-07-30 | $137.50M 10-Q · filed 2021-07-30 | $192.54M derived: sum of 3 quarters · filed 2022-02-09 | $255.96M derived: sum of 4 quarters · filed 2022-02-09 | ||||
| 2020-03-31 | $51.46M 10-Q · filed 2021-04-30 | $106.50M derived: sum of 2 quarters · filed 2022-02-09 | $169.92M derived: sum of 3 quarters · filed 2022-02-09 | $233.49M derived: sum of 4 quarters · filed 2022-02-09 | ||||
| 2019-12-31 | $55.04M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $118.46M derived: sum of 2 quarters · filed 2022-02-09 | $182.03M derived: sum of 3 quarters · filed 2022-02-09 | $236.30M 10-K · filed 2022-02-09 | $236.26M 10-K · filed 2020-02-13 | |||
| 2019-09-30 | $63.42M 10-Q · filed 2020-10-30 | $126.99M derived: sum of 2 quarters · filed 2020-10-30 | $181.26M 10-Q · filed 2020-10-30 | $273.92M derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2019-06-30 | $63.57M 10-Q · filed 2020-07-31 | $117.84M 10-Q · filed 2020-07-31 | $210.49M derived: sum of 3 quarters · filed 2021-02-11 | $299.14M derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2019-03-31 | $54.27M 10-Q · filed 2020-05-01 | $146.93M derived: sum of 2 quarters · filed 2021-02-11 | $235.57M derived: sum of 3 quarters · filed 2021-02-11 | $323.04M derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2018-12-31 | $92.66M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | $181.30M derived: sum of 2 quarters · filed 2021-02-11 | $268.77M derived: sum of 3 quarters · filed 2021-02-11 | $325.05M 10-K · filed 2021-02-11 | ||||
| 2018-09-30 | $88.65M 10-Q · filed 2019-10-31 | $176.11M derived: sum of 2 quarters · filed 2019-10-31 | $232.39M 10-Q · filed 2019-10-31 | |||||
| 2018-06-30 | $87.47M 10-Q · filed 2019-08-01 | $143.74M 10-Q · filed 2019-08-01 | ||||||
| 2018-03-31 | $56.28M 10-Q · filed 2019-05-01 | |||||||
| 2017-12-31 | $293.24M 10-K · filed 2020-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |